GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Frontier Biotechnologies Inc (SHSE:688221) » Definitions » ROIC %

Frontier Biotechnologies (SHSE:688221) ROIC % : -9.25% (As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Frontier Biotechnologies ROIC %?

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Frontier Biotechnologies's annualized return on invested capital (ROIC %) for the quarter that ended in Sep. 2024 was -9.25%.

As of today (2025-03-17), Frontier Biotechnologies's WACC % is 12.27%. Frontier Biotechnologies's ROIC % is -17.66% (calculated using TTM income statement data). Frontier Biotechnologies earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Frontier Biotechnologies ROIC % Historical Data

The historical data trend for Frontier Biotechnologies's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Frontier Biotechnologies ROIC % Chart

Frontier Biotechnologies Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROIC %
Get a 7-Day Free Trial -42.52 -39.06 -32.04 -30.97 -26.10

Frontier Biotechnologies Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -22.85 -25.22 -17.65 -18.69 -9.25

Competitive Comparison of Frontier Biotechnologies's ROIC %

For the Drug Manufacturers - Specialty & Generic subindustry, Frontier Biotechnologies's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Frontier Biotechnologies's ROIC % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Frontier Biotechnologies's ROIC % distribution charts can be found below:

* The bar in red indicates where Frontier Biotechnologies's ROIC % falls into.



Frontier Biotechnologies ROIC % Calculation

Frontier Biotechnologies's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2023 is calculated as:

ROIC % (A: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2022 ) + Invested Capital (A: Dec. 2023 ))/ count )
=-330.517 * ( 1 - 0% )/( (1176.127 + 1356.741)/ 2 )
=-330.517/1266.434
=-26.10 %

where

Invested Capital(A: Dec. 2022 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2410.859 - 105.885 - ( 1241.007 - max(0, 277.23 - 1406.077+1241.007))
=1176.127

Invested Capital(A: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2140.126 - 60.757 - ( 941.721 - max(0, 380.158 - 1102.786+941.721))
=1356.741

Frontier Biotechnologies's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Sep. 2024 is calculated as:

ROIC % (Q: Sep. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2024 ) + Invested Capital (Q: Sep. 2024 ))/ count )
=-128.856 * ( 1 - 0% )/( (1399.134 + 1385.844)/ 2 )
=-128.856/1392.489
=-9.25 %

where

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2057.173 - 67.995 - ( 858.623 - max(0, 473.455 - 1063.499+858.623))
=1399.134

Invested Capital(Q: Sep. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2005.628 - 76.561 - ( 662.468 - max(0, 476.223 - 1019.446+662.468))
=1385.844

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Frontier Biotechnologies  (SHSE:688221) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Frontier Biotechnologies's WACC % is 12.27%. Frontier Biotechnologies's ROIC % is -17.66% (calculated using TTM income statement data).


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Frontier Biotechnologies ROIC % Related Terms

Thank you for viewing the detailed overview of Frontier Biotechnologies's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Frontier Biotechnologies Business Description

Traded in Other Exchanges
N/A
Address
No. 5 Gande Road, 7th Floor, Science Park, Jiangning District, Jiangsu Province, Nanjing, CHN, 211122
Frontier Biotechnologies Inc is an innovative biomedical company. It is engaged in the production and sales of innovative drugs for major unmet clinical needs. The company focuses on the research and development of new drugs in the field of long-acting peptides and differentiated product development strategies for unmet clinical and patient needs.

Frontier Biotechnologies Headlines

No Headlines